https://www.preprints.org/manuscript/202605.0364
Bispecific T-Cell Engager Clinical Translation Is Not Predicted by Target Antigen Density Alone: A...
Bispecific T-cell engager (TCE) development continues to attract substantial industrial investment alongside a translation record that remains uneven across...
bispecific t cell engager
https://www.biospace.com/xencor-regains-cd20-x-cd3-bispecific-t-cell-engager
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager - BioSpace
Jun 14, 2024 - Xencor, Inc. announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1...
bispecific t cell engagerregainscd20xcd3